|

GM-CSF With Post-Transplant Cyclophosphamide

RECRUITINGPhase 2Sponsored by Northside Hospital, Inc.
Actively Recruiting
PhasePhase 2
SponsorNorthside Hospital, Inc.
Started2020-05-18
Est. completion2026-09-18
Eligibility
Age18 Years – 78 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04237623

Summary

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

Eligibility

Age: 18 Years – 78 YearsHealthy volunteers accepted
Inclusion Criteria:

* Availability of 5/10 to 8/10 matched related donor
* KPS \>/= 70%
* CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center

Exclusion Criteria:

* Poor cardiac, pulmonary, liver, and renal function
* HIV-positive
* Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent
* History of severe or serious allergic reaction to human GM-CSF or yeast-derived products

Conditions2

CancerTransplant-Related Hematologic Malignancy

Locations1 site

Northside Hospital
Atlanta, Georgia, 30342
Stacey Brown, BA404-780-7965stacey.brown@northside.com

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.